Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Phase II Clinical Study of Darsilide Combined With Exemestane+Goserelin Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

A multicenter, prospective, open, randomized cohort, non controlled phase II clinical study to evaluate the effectiveness and safety of Darxil combined with Exemestane+goserelin neoadjuvant endocrine therapy in HR positive and HER2 negative premenopausal breast cancer patients. The study object was to evaluate the HR positive and HER2 negative premenopausal breast cancer patients with SD after 2 cycles of neoadjuvant chemotherapy. The main endpoint was the objective response rate (ORR) of treatment

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection; Drug: dalpiciclib、Exemestane、Gosserine

Detailed Description

A multicenter, prospective, open, randomized cohort, non controlled phase II clinical study to evaluate the effectiveness and safety of Darxil combined with Exemestane+goserelin neoadjuvant endocrine therapy in HR positive and HER2 negative premenopausal breast cancer patients. The study object was to evaluate the HR positive and HER2 negative premenopausal breast cancer patients with SD after 2 cycles of neoadjuvant chemotherapy. The main endpoint was the objective response rate (ORR) of treatment。Objective: To evaluate the efficacy and safety of darsilide combined with endocrine therapy in SD patients with HR positive and HER2 negative premenopausal breast cancer after 2 cycles of neoadjuvant chemotherapy. It is planned to recruit 119 HR positive and HER2 negative premenopausal breast cancer patients in Group A to conduct the trial with Simon's two-stage design. The null hypothesis is a true response rate of 0.2, while the alternative hypothesis is a true response rate of 0.4. The experiment was conducted in two stages. In the first stage, 13 patients were enrolled. If there are ≤ 3 responses in 13 patients, the study will be stopped Early stopping. Otherwise, continue30 patients were enrolled, with a total sample size of 43. If there are ≥ 13 patients responding, the treatment is effective. Group B was randomly assigned in a 1:1 ratio, with the same number of participants as Group A, resulting in 43 final participants. Calculated based on the proportion of SD patients in 2 cycles of neoadjuvant chemotherapy accounting for 80%, and considering a 10% dropout rate, the final enrollment was made The sample size is 119 cases. The actual samples for molecular testing can be randomly selected based on clinical efficacy, with a statistically significant number.

• Study Type: Interventional
• Enrollment (Actual): 119
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• China
  • Tianjin Municipality
    • Tianjin, Tianjin Municipality, China, 300000
      • Jie Ge

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• All patients were operable estrogen receptor (ER) positive (>1%), regardless of PR expression level, HER2 receptor negative invasive breast cancer. Follow the 2018 ASCO-CAP HER2 negative interpretation guideline standard. Confirmed by the pathological laboratory that the immunohistochemical (IHC) score is 0 or 1-2+and the in situ hybridization (ISH) test is negative (ISH amplification rate<2.0);
• Stage II-III initial treatment patients whose tumor staging meets the AJCC 8th edition standards;
• At least one measurable breast and/or axillary disease;
• ECOG 0-1, with an estimated lifespan of at least 12 months;
• The functional level of the main organs must meet the following requirements:

Blood routine: ANC ≥ 1.5 × ten9/L; PLT ≥ 90 × ten9/L; Hb ≥ 90 g/L;Blood biochemistry: TBIL ≤ 2.5 × ULN; ALT and AST ≤ 2.5 × ULN; BUN and Cr≤ 1.5 × ULN;

• Lead ECG: QT interval (QTcF) corrected by Fridericia method<470 ms for women;
• Able to accept all puncture biopsies required by the protocol;
• Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up;
• Women with fertility potential must have a negative Pregnancy test (urine or serum) within 7 days after administration,

And agree to use acceptable birth control methods during the study period to avoid pregnancy.

Exclusion Criteria:

• Received any form of anti-tumor treatment within 28 days prior to the start of the study;
• Simultaneously receiving any anti-tumor treatment beyond the provisions of other protocols;
• Bilateral breast cancer, inflammatory breast cancer or occult breast;
• Stage IV breast cancer;
• Severe dysfunction of important organs such as heart, liver, and kidney;
• Unable to swallow, chronic diarrhea and Bowel obstruction, there are many factors that affect drug taking and absorption;
• Participated in other drug clinical trials within 4 weeks prior to enrollment;
• Those with a known history of allergies to the drug components of this protocol; Have a history of immunodeficiency, including positive Diagnosis of HIV/AIDS test Sex, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases Illness or a history of organ transplantation;
• Have ever suffered from any heart disease, including: (1) arrhythmia that requires medication or has clinical significance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Docetaxel, epirubicin hydrochloride, Cyclophosphamide; SD patients undergoing 2 cycles of preoperative treatment were randomly assigned to Group B and received TAC chemotherapy	Drug: Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection; Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time Calculate, otherwise terminate treatment. 5. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise Stop treatment. 6. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat
Experimental: dalpiciclib+Goserelin+Exemestane; SD patients undergoing 2 cycles of preoperative treatment were randomly assigned to Group A and received darcelli, Exemestane, and Goserelin	Drug: dalpiciclib、Exemestane、Gosserine; dalpiciclib: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication Fasting for 1 hour before and after. Exemestane: 25mg, oral, once a day, continuous administration. Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR) for treatment	The proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time limit requirement	At the end of the second cycle (each cycle is 21 or 28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor residual load	The number of cancer cells, tumor size, or total number of cancer lesions in the human body after surgery	At the end of the 6 cycle (each cycle is 21 or 28 days)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Breast retention rate	Postoperative breast preservation ratio	At the end of the 6 cycle (each cycle is 21 or 28 days)
Event free lifetime	The time from the start of randomized clinical trials to the progression of tumors (in any aspect) or death from any cause	At the end of the 6 cycle (each cycle is 21 or 28 days)
Overall survival (OS)	Time from randomization to death from any cause	2years

Collaborators and Investigators

• Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Investigators: Study Director: jie 1 ge, 1, yes

Study record dates

Study Major Dates

• Study Start (Actual): April 11, 2023
• Primary Completion (Actual): March 11, 2025
• Study Completion (Actual): September 11, 2025

Study Registration Dates

• First Submitted: July 18, 2023
• First Submitted That Met QC Criteria: August 20, 2023
• First Posted (Actual): August 24, 2023

Study Record Updates

• Last Update Posted (Actual): February 10, 2026
• Last Update Submitted That Met QC Criteria: February 5, 2026
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms; Organic Chemicals; Therapeutics; Drug Administration Routes; Drug Therapy; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Taxoids; Cyclodecanes; Diterpenes; Docetaxel; Injections
• Other Study ID Numbers: Tianjin Hospital Cancer

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No